The demonstrated efficacy and favorable safety profile of remestemcel-L address a significant unmet medical need in pediatric SR-aGVHD patients, especially in children under the age of 12 years old. Considered in the context of a serious condition for which currently available treatments have limitations, the totality of evidence substantiates the highly favorable clinical benefit-risk profile for remestemcel-L in the treatment of pediatric patients with SR-aGVHD.
sounds positive to me
MESO action tonight, page-1661
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |